In a recent study published in the Journal of Clinical Medicine and Pharmaceuticals, researchers found that melatonin protects from kidney damage caused by obesity with type 2 diabetes.
They found that chronic administration of melatonin at doses (10 mg/kg body weight/day) prevents kidney cell damage and its progression to kidney failure.
The study is from the University of Granada. One author is Ahmad Agil.
Kidney damage is caused by metabolic complications of obesity, such as diabetes, hypertension, blood lipid disorders, or fatty liver disease.
Melatonin is a hormone primarily released by the pineal gland at night and has long been linked to control of the sleep-wake cycle.
As a dietary supplement, it is often used for the short-term treatment of insomnia.
It has been shown that melatonin prevents the impairment of the function and dynamics of cellular mitochondria, decreasing the increased production of oxygen free radicals (responsible for oxidative stress).
The team says the current study shows the efficacy of melatonin in fighting renal damage, and it provides an alternative preventive treatment that would improve kidney function with a well-studied drug.
These results are in line with evidence that melatonin may play a role in fighting diabesity (central obesity and its type 2 diabetes) and its complications (such as hepatic steatosis, hypertension, lipid alteration, etc.).
According to the results, melatonin could help treat kidney damage, which establishes the need to develop new clinical trials to test its effectiveness.
If you care about kidney health, please read studies about this muscle drug may affect cognitive ability in people with kidney diseases and findings of these blood fats could cause inflammation, harm blood vessels and kidneys.
For more information about kidney diseases, please see recent studies about this stuff in blood could protect against heart failure, kidney damage and results showing that this kidney problem linked to heart failure.
Copyright © 2021 Knowridge Science Report. All rights reserved.
